By virtue of a contract, since 2014 Pfizerhas held exclusive rights - in the U.S., Europe and the rest of the world - to distributeAstraZeneca's over-the-counterNEXIUM (esomeprazole magnesium), a leading prescription drug currently approved to treat the symptoms of gastro-esophageal reflux disease (GERD). SupposePfizer's monopsony and monopoly power from this exclusive deal forNEXIUMis earning unexpectedly huge profits. Is this sufficient justification forAstraZenecato buy outPfizer? Explain